RISK ATTITUDE
THE IMPACT OF HOSPITAL COSTING METHODS ON STATISTICAL POWER IN MULTINATIONAL CLINICAL TRIALS
RESPONSE BIAS AMONG LIKELY CLINICAL TRIAL PARTICIPANTS
CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES?
COST-EFFECTIVENESS OF AIRLINE DEFIBRILLATORS
ANALYSIS OF THE IMPACT OF ASSISTIVE LIVING DEVICES ON SELF–ASSESSED HEALTH STATUS RATING
THE DIAGNOSTIC ACCURACY OF 18FDG-PET IN PATIENTS WITH RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER
INCLUSION OF INDIRECT COST IN ECONOMIC OUTCOMES ANALYSES OF MEDICAL DEVICES
DOES SOCIOECONOMIC STATUS AFFECT THE VALUATION OF HEALTH?
LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH
QUALITY OF LIFE IN PRODUCT LABELING
QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990–99
ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)
THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS
INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS
ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES
UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR)
EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT
COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN+5FU/FA ALONE AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER IN THE UK
ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK
THE VALUE OF COMPLIANCE
INDIRECT COMPARISONS OF DRUGS USING META–ANALYSIS
DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS?
USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION
THE COST-EFFECTIVENESS OF LIFETIME FACTOR VIII PROPHYLAXIS IN THE TREATMENT OF SEVERE HEMOPHILIA A
ECONOMIC EVALUATION OF DALTEPARIN, ENOXAPARIN AND UNFRACTIONATED HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS
COST-EFFECTIVENESS OF CARDIOVASCULAR DISEASE (CVD) PREVENTION BY REDUCING POSTPRANDIAL HYPERGLYCEMIA
WORK-RELATED OUTCOMES OF PATIENTS SIX MONTHS AFTER MYOCARDIAL INFARCTION
THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE
THE INCREMENTAL COST OF DIABETES IN CHRONIC ILLNESS CO-OCCURRENCES
A RETROSPECTIVE EVALUATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS AMONG ADULTS IN A MANAGED CARE HEALTH PLAN
DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTH CARE PLAN
DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT
HEALTH VALUES FOR THE LIPODYSTROPHY SYNDROME
COST-EFFECTIVENESS ANALYSIS OF AN INTRANASAL INFLUENZA VACCINE FOR HEALTHY CHILDREN
THE CONFUSION BETWEEN SEPTICEMIA AND SEVERE SEPSIS
THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA
FUTURE EMPLOYABILITY
CLINICAL ASSESSMENT OF QUALITY OF LIFE AMONG SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME
APPLICATION OF THE RASCH MODEL TO THE SF36 MENTAL HEALTH 5 ITEM SCALE (MH5)
COST-EFFECTIVENESS OF INTERVENTIONS FOR LATERAL EPICONDYLITIS
RESPONSIVENESS TO CHANGE OF THE SF-36 IN RAPOLO, A LONGITUDINAL STUDY OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ETANERCEPT
CORRELATION OF A GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE AND SELF-ADMINISTERED RHEUMATOID ARTHRITIS DISEASE ACTIVITY INSTRUMENT
A SYSTEMATIC REVIEW OF HEALTH STATE VALUES FOR OSTEOPOROSIS RELATED CONDITIONS
OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA
USING SELF-ADMINISTERED DIRECT TTO QUESTIONS TO ELICIT UTILITY VALUES FOR ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE
PSYCHOMETRIC EVALUATION OF THE CAP-SYM QUESTIONNAIRE
A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA
JOINT COUNTS IN PATIENTS WITH NEW ONSET RHEUMATOID ARTHRITIS
AN ECONOMIC EVALUATION OF OSTEOPOROSIS MEDICATION USE PATTERNS IN A MANAGED CARE ORGANIZATION
THE COST OF OSTEOPOROTIC FRACTURES IN THE UNITED KINGDOM
USE OF COX 2 NSAIDS IN SUBJECTS WITHOUT RISK OF GASTROINTESTINAL SIDE EFFECTS
INVESTIGATING THE CONSTRUCT VALIDITY OF A DISEASE SPECIFIC AND A GENERAL QUALITY OF LIFE INSTRUMENTS OF PATIENTS WITH RHEUMATOID ARTHRITIS
COST-EFFECTIVENESS OF ROFECOXIB VERSUS NSAIDS IN THE TREATMENT OF OSTEOARTHRITIS
THE CORRELATION BETWEEN ARTHRITIS SPECIFIC MEASURES AND SF-36 SCALES IN RHEUMATOID ARTHRITIS PATIENTS
COST COMPARISON OF TREATING OSTEOPOROSIS PATIENTS WITH ESTROGENS OR SELECTIVE ESTROGEN RECEPTOR MODULATOR IN A MANAGED CARE POPULATION
COST COMPARISON OF TREATING RHEUMATOID ARTHRITIS PATIENTS WITH COX-2 INHIBITORS OR NSAIDS IN A MANAGED CARE POPULATION
THE IMPACT OF EARLY RHEUMATOID ARTHRITIS ON PRODUCTIVITY
APPLYING BACKGROUND RISK DISTRIBUTION TO EVALUATE THE COST-EFFECTIVENESS OF THREE PREVENTIVE DRUG THERAPIES FOR OSTEOPOROTIC FRACTURES
COST-MINIMIZATION ANALYSIS OF THE TREATMENT OF RHEUMATOID ARTHRITIS WITH LEFLUNOMIDE IN COMPARISON WITH THE COMBINATION OF INFLIXIMAB AND METHOTREXATE
A COST-EFFECTIVENESS MODEL COMPARING CELECOXIB AND ROFECOXIB TO TRADITIONAL NSAIDS FOR OSTEOARTHRITIS TREATMENT
TREATMENT WITH LEFLUNOMIDE IMPROVES THE UTILITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
EVALUATING DIRECT AND INDIRECT MEASURES OF UTILITY
COST IMPACT OF COX-2 INHIBITORS IN A MANAGED CARE PLAN
IMPORTANT ISSUES IN NUMBER NEEDED TO TREAT ANALYSIS IN OSTEOPOROSIS TREATMENT
PERFORMANCE ASSESSMENT OF TWO FATIGUE INSTRUMENTS IN AN EARLY RHEUMATOID ARTHRITIS COHORT
A REVIEW OF FUNCTIONAL STATUS MEASURES FOR WORKERS WITH UPPER EXTREMITY DISORDERS
COST-EFFECTIVENESS OF ACETYLCISTEINE AND DIMETHYLSULPHOXIDE (DMSO) 50% FOR THE TREATMENT OF PATIENTS WITH REFLEX SYMPATHIC DYSTROPHY
MANUAL THERAPY IS MORE COST-EFFECTIVE THAN PHYSICAL THERAPY AND GP CARE FOR PATIENTS WITH NECK PAIN
STUDYING PREDICTORS OF FRACTURES AMONG OMNICARE NURSING HOME RESIDENTS
VERTEBRAL FRACTURES AMONG GLUCOCORTICOID PATIENTS SIGNIFICANTLY INCREASE MEDICAL CARE COSTS
COST OF ASTHMA IN CHILDREN IN VLADIVOSTOK
USE OF RESPIRATORY ASSIST DEVICES BY MEDICARE BENEFICIARIES
THE STANDARDIZED ASTHMA-RELATED QUALITY OF LIFE QUESTIONNAIRE (AQLQ-S)
COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS
PROPHYLACTIC MEDICATION UTILIZATION AND HEALTH CARE COSTS IN OLDER ADULTS WITH CHRONIC PULMONARY AILMENTS
VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE
A COST-EFFECTIVENESS ANALYSIS COMPARING LEVALBUTEROL AND ALBUTEROL IN THE TREATMENT OF MODERATE TO SEVERE ASTHMA
VALIDATION OF A RATING INSTRUMENT ASSESSING THE INHALATION SKILLS OF CHILDREN WITH ASTHMA
IMPLEMENTING RASCH ANALYSIS IN PSYCHOMETRIC EVALUATION OF PATIENT-PHYSICIAN INTERACTION SCALE
THE LONG-TERM SOCIETAL ECONOMIC AND HUMANISTIC BENEFITS OF TREATING ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) WITH GEMIFLOXACIN VERSUS CLARITHROMYCIN
PROSPECTIVE USE OF WEB BASED TECHNOLOGY TO EVALUATE HEALTH OUTCOMES IN A LARGE COHORT OF SEVERE OR DIFFICULT TO TREAT ASTHMATICS
HYPOTHETICAL VERSUS REAL WILLINGNESS TO PAY IN THE HEALTH CARE SECTOR
ASSESSMENT OF THE RELATIONSHIP BETWEEN DISEASE SEVERITY, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA
COMPARISON OF HEALTH CARE RESOURCE UTILIZATION OF COPD PATIENTS ON CILOMILAST, 15 MG BID VERSUS PLACEBO
COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION
PATIENT SATISFACTION WITH NON-SEDATING ANTIHISTAMINES
COSTS OF TREATING COPD IN ITALY
IMPACT OF THE ADDITION OF SALMETEROL TO THE TREATMENT OF ASTHMA PATIENTS IN A MEDICAID FEE-FOR-SERVICE POPULATION
EFFECTIVENESS OF COMPLIANCE ON HEALTH CARE RESOURCE USE IN ASTHMA PATIENTS TREATED WITH MONTELUKAST VS. INHALED CORTICOSTEROIDS
LEVALBUTEROL USE IS ASSOCIATED WITH DECREASED HEALTH CARE COSTS IN PATIENTS WITH MORE SEVERE ASTHMA
IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES
DETERMINANTS OF INAPPROPRIATE ANTIBIOTIC PRESCRIBING
CATEGORIZATION OF RISK OF PROSTATE CANCER
WHICH VARIABLES DO METASTATIC BREAST CANCER PATIENTS AND ONCOLOGY NURSES ANCHOR ON WHEN USING THE EUROQOL DESCRIPTIVE SYSTEM IN MEASURING UTILITIES WITH THE STANDARD GAMBLE TECHNIQUE?
PREDICTORS OF CHEMOTHERAPY-RELATED NEUTROPENIA
COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES
DOCETAXEL/DOXORRUBICIN (DD) AS FIRST LINE CHEMOTHERAPY
CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS?
ECONOMIC EVALUATION OF GEMZAR AND BEST SUPPORTIVE CARE (BSC) RELATIVE TO BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK
ECONOMIC EVALUATION OF GEMZAR IN THE TREATMENT OF PANCREATIC CANCER IN THE UK
ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK
COST-EFFECTIVENESS MODEL OF PROSTATE-SPECIFIC ANTIGEN (PSA) SCREENING FOR PROSTATE CANCER
ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK
COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER
COST OF THROMBOCYTOPENIA-RELATED BLEEDING AMONG PATIENTS WITH CANCER
CHOICE OF LOCALIZED BREAST CANCER TREATMENTS IN A MEDICARE POPULATION
DIFFERENCES BETWEEN PREFERENCES FOR HEALTH STATES
CHEMOTHERAPY TREATMENT IN NEWLY DIAGNOSED BREAST CANCER PATIENTS IN A MANAGED CARE POPULATION
AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF ADVANCED COLORECTAL CANCER IN THE UK
COLORECTAL CANCER SCREENING
COLORECTAL CANCER SCREENING TESTS
COST MINIMIZATION ANALYSIS OF CEFEPIME VERSUS IMIPENEM-CILASTATINE IN CANCER PATIENTS WITH SHORT-DURATION FEBRILE NEUTROPENIA
HEALTH-RELATED QUALITY OF LIFE AFTER ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER
COST-EFFECTIVENESS ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER
DISEASE MODELING
INCIDENCE AND COST OF HOSPITALIZATION FOR 5-FU TOXICITY AMONG MEDICARE BENEFICIARIES WITH METASTATIC COLORECTAL CANCER
A QUALITY OF LIFE AUDIT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING CHEMOTHERAPY AT ONE INSTITUTION
SYSTEMATIC ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER
COST OF TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN THE UNITED STATES
DETECTING RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER IN CLINICALPRACTICE
A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN AS PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH ESTABLISHED PERIPHERAL ARTERY DISEASE
VENOUS THROMBOEMBOLIC (VTE) COMPLICATIONS FOLLOWING MAJOR ORTHOPEDIC SURGERY
AN ANALYSIS OF THE COST OF ADVERSE EVENTS ASSOCIATED WITH THE USE OF HMG-COA REDUCTASE INHIBITORS
ASSESSING QUALITY OF LIFE IN PATIENTS SIX MONTHS AFTER A MYOCARDIAL INFARCTION USING THE SF-12
COST OF TREATMENT AND PREVALENCE OF CARDIOVASCULAR DISEASE COMORBIDITIES AND RISK FACTORS IN THE SEVERE AND PERSISTENTLY MENTALLY ILL
ESTIMATING INCREMENTAL COSTS FOR ADDITIONAL HOSPITAL DAYS
COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION
PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS
AN ECONOMIC ANALYSIS OF CONGESTIVE HEART FAILURE (CHF) IN THE LOUISIANA MEDICAID PROGRAM
INCIDENCE OF RHABDOMYOLYSIS IN PATIENTS INITIATED ON HMG CO-A REDUCTASE INHIBITOR THERAPY IN A MANAGED CARE ORGANIZATION
COST OF WARFARIN TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE
QUALITY OF CARE IN OLDER PATIENTS ADMITTED TO HOSPITAL WITH HEART FAILURE
IMPACT ON QUALITY ADJUSTED LIFE YEARS OF ENOXAPARIN FOR PREVENTING THROMBOSIS AMONG HOSPITALIZED MEDICAL PATIENTS
IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
ECONOMIC EVALUATION OF OUTPATIENT ANTICOAGULANT/ANTIPLATELET THERAPY FOLLOWING CORONARY STENTING IN A MANAGED CARE POPULATION
COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME PATIENTS IN POLAND
QUALITY OF LIFE AND PATIENT PREFERENCE AS PREDICTORS FOR RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE; INTERIM ANALYSIS
FRAMINGHAM RISK EQUATIONS PREDICT HOSPITAL USAGE AND MORTALITY
DISCRIMINABILITY FOR RISK OF CARDIOVASCULAR EVENTS
ASSESSING THE TOTAL COST OF MANAGEMENT OF A PATIENT WITH DEEP VEIN THROMBOSIS (DVT) IN FRANCE AND IN ITALY
COST-EFFECTIVENESS ANALYSIS OF ABCIXIMAB, EPTIFIBATIDE, AND TIROFIBAN IN PATIENTS WITH CORONARY SYNDROMES
IN-PATIENT AND OUT-PATIENT RESOURCE UTILIZATION AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE—THE VA EXPERIENCE
PHARMACOECONOMIC EVALUATION OF USAGE OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS IN LONG-TERM CARE RESIDENTS
BEYOND THE FIRST YEAR
CHD RISK FACTORS AND THERAPY DURATION OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN A MEDICAID POPULATION
CARING FOR HYPERTENSION ON INITIATION
A PHARMACOECONOMIC MODEL TO EVALUATE TREATMENT OPTIONS FOR DVT PHARMACOPROPHYLAXIS
CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER
ECONOMIC OUTCOMES OF PATIENTS RECEIVING CARVEDILOL COMPARED TO THOSE RECEIVING NO BETA-BLOCKER THERAPY FOR THE TREATMENT OF CONGESTIVE HEART FAILURE IN A MANAGED CARE ORGANIZATION
COST-EFFECTIVENESS MODEL OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION
CLOSURE OF ATRIAL SEPTAL DEFECT
STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS
COST-ANALYSIS OF CABG SURGERY IN PATIENTS WITH AND WITHOUT RETHORACOTOMY FROM THE HOSPITAL PERSPECTIVE IN GERMANY
DECISION ANALYSIS MODEL OF ABCIXIMAB, EPTIFIBATIDE OR STANDARD THERAPY IN ELECTIVE STENT PLACEMENT
COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY
EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATA
THE COST-EFFECTIVENESS OF STATINS
COST OF TREATMENT OF HYPERCHOLESTEROLAEMIA TO NHF GOALS IN AUSTRALIA
COST-EFFECTIVENESS OF LIPID LOWERING INTERVENTIONS IN A NATIVE AMERICAN CARDIOVASCULAR RISK REDUCTION PROGRAM
SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442— ONE-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY
PATIENTS' WILLINGNESS TO PAY FOR PHARMACIST MANAGED WARFARIN THERAPY AT COMMUNITY PHARMACIES
DIABETIC MANAGEMENT THROUGH ORAL GLUCOSE LOWERING AGENTS
USING RETROSPECTIVE CLAIMS DATA TO DESIGN CLINICAL SAFETY SURVEILLANCE OF THIAZOLIDINEDIONE DRUGS
THE BURDEN OF ILLNESS OF DIABETES MELLITUS TYPE 2 IN GERMANY— A PILOT STUDY
COST-EFFECTIVENESS AND CARDIOVASCULAR RISK—AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
A COST-MINIMIZATION STUDY TO DETERMINE THE IMPACT OF ADDING GLUCOVANCE TO A COUNTY HOSPITAL FORMULARY
AN EARLY LOOK AT TZD USE AMONG TYPE 2 DIABETES PATIENTS
COSTS AND EFFECTIVENESS OF INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES
FACTORS ASSOCIATED WITH PRESCRIPTION CLAIMS FOR BLOOD GLUCOSE TEST STRIPS AMONG FEE-FOR-SERVICE NEW MEXICO MEDICAID PATIENTS
COST-EFFECTIVENESS ANALYSIS OF A MULTIDISCIPLINARY DIABETES CARE CLINIC
THE COST OF NEW ONSET DIABETES MELLITUS AMONG US RENAL TRANSPLANT RECIPIENTS
ECONOMIC OUTCOMES OF DIABETES AMONG AN EMPLOYED POPULATION
A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE
OPTIMIZATION OF DIABETES MANAGEMENT IN GERMANY USING A COMPUTER BASED OUTCOME PROGNOSES MODEL
IMPACT OF A DIABETES DISEASE MANAGEMENT PROGRAM
DOES PATIENT EXPERIENCE MATTER? TYPE II DIABETES PATIENTS' STATED PREFERENCES FOR INSULIN THERAPIES
AN OVERVIEW OF PHARMACOECONOMICS IN TURKEY
ANTIBIOTIC PRESCRIBING PATTERNS FOR THE TREATMENT OF INITIAL ACUTE OTITIS MEDIA IN CHILDREN ENROLLED IN IOWA MEDICAID FROM 1990 THROUGH 1997
THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYER'S PERSPECTIVE
DRY-EYE RELATED INCREASES IN HEALTH CARE UTILIZATION AND EXPENDITURES
THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX
INAPPROPRIATE ANTIBIOTIC PRESCRIBING AND ECONOMIC OUTCOMES FOR PEDIATRIC OTITIS MEDIA
COST-EFFECTIVENESS OF ARTIFICIAL SKIN SUBSTITUTE VS ALLOGRAFT FOR BURN PATIENTS
A COST COMPARISON STUDY OF COMMON PRACTICE AND BEST PRACTICE TREATMENT FOR PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES
FOUR YEAR COST-EFFECTIVENESS OF INITIAL TRABECULECTOMY VERSUS CONVENTIONAL THERAPY IN PRIMARY OPEN-ANGLE GLAUCOMA (POAG)
EFFECTS ON HEALTH CARE CONTACTS AND DAYS ABSENT FROM WORK WITH BUDESONIDE CIR CAPSULES IN THE MAINTENANCE TREATMENT OF CROHN'S DISEASE IN A US SETTING
ALTERNATIVE MANAGEMENT STRATEGIES FOR DYSPEPSIA
A PROSPECTIVE, RANDOMIZED COST ANALYSIS OF MEPERIDINE AND MIDAZOLAM VERSUS PROPOFOL FOR COMPLEX UPPER ENDOSCOPY PROCEDURES
HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA REVEAL DIFFERENCES AMONG CLINICAL “RESPONDERS”
HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHN'S DISEASE
COST-EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI ERADICATION TRIPLE THERAPY VERSUS CONVENTIONAL THERAPY FOR GASTRIC AND DUODENAL ULCERS IN JAPAN
BUDESONIDE CIR IS COST-EFFECTIVE IN MAINTENANCE THERAPY OF CROHN'S DISEASE IN FINLAND
RAPID IMPACT OF RABEPRAZOLE ON SYMPTOM DISTRESS AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
COST-EFFECTIVENESS OF ‘TEST&TREAT’ HELICOBACTER PYLORI INFECTED DYSPEPTIC PATIENTS IN A PRIMARY CARE SETTING
IRRITABLE BOWEL SYNDROME COSTS SICKNESS FUNDS DM 2.8 BILLION PER YEAR
CHARACTERIZATION AND MARKOV MODELING OF GASTROESOPHAGEAL REFLUX DISEASE STATES IN A LARGE HEALTH CARE PLAN
ESTIMATING POTENTIAL UTILIZATION OF ESOMEPRAZOLE BY ASSESSING GERD SYMPTOM CONTROL ON TRADITIONAL PPI'S
FACTORS ASSOCIATED WITH PHYSICIAN KNOWLEDGE OF WHETHER PRESCRIPTION DRUGS ARE ON FORMULARY
HOW IMPORTANT IS APPROPRIATE EMPIRICAL ANTIBIOTIC TREATMENT FOR INTRA-ABDOMINAL INFECTIONS?
COMPUTERIZED ASSESSMENT OF COMPLICATIONS FOLLOWING COLORECTAL SURGERY
ANALYSIS OF THE LONG-TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE
COMPARISON OF GENERIC VERSUS DISEASE SPECIFIC TOOLS FOR THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CROHN'S DISEASE
EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS
IMPACT OF CYTOMEGALOVIRUS (CMV)-RELATED READMISSION ON POST HEART TRANSPLANT RESOURCE USE
TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES
ECONOMIC COST OF HIV INFECTION IN UNTREATED WORKERS
MOXIFLOXACIN VS AMOXICILLIN/CLAVULANATE IN THE TREATMENT OF ACUTE MAXILLARY SINUSITIS (ams)
HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS
OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS
COSTS OF HEALTH CARE FOR HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)
COST-EFFECTIVENESS OF INTERFERON ALFA THERAPY FOR CHRONIC HEPATITIS C WITH CIRRHOSIS
EFFECTS OF LINEZOLID ON HOSPITAL LENGTH OF STAY IN METHICILLIN-RESISTANT STAPHYLOCOCCUS INFECTIONS ESTIMATED FROM MULTIVARIATE SURVIVAL ANALYSIS
PEGYLATED (40KDA) INTERFERON ALFA-2A (PEGASYS®) SIGNIFICANTLY IMPROVES TOLERABILITY, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C
AVERTING FUTURE AIDS CASES
ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION FOR THE NETHERLANDS
PREDICTORS OF THE MENTAL (MHS) AND PHYSICAL HEALTH SUMMARY (PHS) SCORES OF THE MOS-HIV IN A SAMPLE OF HIV-INFECTED PATIENTS
MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY
COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING
ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN
METHICILLIN-RESISTANT STAPHYLOCOCCUS SPECIES TREATMENT PATTERNS IN CANADA
AN ECONOMIC ANALYSIS OF CEFDINIR VERSUS LORACARBEF FOR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS
TARGETING POPULATIONS AT-RISK FOR URINARY TRACT INFECTION COMPLICATION
THE COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE IN THE TREATMENT OF CHRONIC HEPATITIS B IN POLAND
AN APPRAISAL OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN PATIENTS DIAGNOSED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
PATTERNS OF ANTIBIOTIC USE AND COSTS ASSOCIATED WITH EPISODES OF TREATMENT FOR COMMON OUTPATIENT RESPIRATORY-TRACT INFECTIONS
COST COMPARISON OF GATIFLOXACIN VERSUS LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN AN OUTPATIENT POPULATION
ECONOMIC EVALUATION OF MACROLIDES AND FLUOROQUINOLONES FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS
PHARMACOECONOMIC EVALUATION OF CEFUROXIME IN ABDOMINAL HYSTERECTOMY
DOES A DAY STILL MAKE A DIFFERENCE? A DECISION ANALYSIS OF ADULT STREPTOCOCCAL PHARYNGITIS
COMPARING DIFFERENCES IN CLINICAL EFFECTIVENESS, NEPHROTOXICITY, AND COST-EFFECTIVENESS OF AMINOGLYCOSIDE THERAPY BETWEEN ALTERNATIVE DOSING PROTOCOLS
SHOULD THE 51 ITEMS OF THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP-51) BE WEIGHTED?
TREATMENT COURSE AND CHARGES FOR DEPRESSED PATIENTS TREATED WITH SERTRALINE, VENLAFAXINE, AND VENLAFAXINE XR IN THE MANAGED CARE SETTING
IS DEPRESSION THE MAJOR CAUSE OF IMPAIRED QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS?
ASSESSMENT OF PATIENTS' ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL
FROM FIRST TO SECOND
CHANGE IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS
CHANGE IN MALADAPTIVE BEHAVIORS ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS
IMPACT OF CURRENT ANTIDEPRESSANTS ON COGNITION IN OLDER PATIENTS WITH DEPRESSION
HEALTH CARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION
HEALTH OUTCOMES OF CHILDHOOD ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)
PREVALENCE OF COMORBID ANXIETY AND DEPRESSION AMONG PATIENTS PRESCRIBED SSRI MONOTHERAPY
PRE-TREATMENT PATIENT DIFFERENCES
DEFICIT SYNDROME AND DRUG USE PATTERNS IN COMMUNITY-BASED SCHIZOPHRENIA CARE
A RETROSPECTIVE ECONOMIC EVALUATION OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
USE OF RASCH MODELS FOR VALIDATION OF INSTRUMENTS USED IN MENTAL HEALTH EVALUATION
TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION
RISK OF HOSPITALIZATION FOR PATIENTS WITH BIPOLAR DISORDER
DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS
QUALITY OF LIFE OF NON-INSTITUTIONAL CAREGIVERS OF SCHIZOPHRENIC PATIENTS
PATTERNS OF ANTIDEPRESSANT USE AND HEALTH CARE COSTS IN DEPRESSED PATIENTS WHO RECEIVED SSRI THERAPY
DEINSTITUTIONALIZATION OF SCHIZOPHRENIC PATIENTS
THE COST OF ACUTE HOSPITALIZATION FOR ANOREXIA NERVOSA AND BULIMIA
A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA
OUTPATIENT ANTIPSYCHOTIC USE
COST-UTILITY ANALYSIS OF QUETIAPINE COMPARED TO RISPERIDONE IN THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS
DEPRESSION AND HOMELESSNESS, A FRENCH INITIATIVE
COST ANALYSIS OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF UNCONTROLLED SCHIZOPHRENIA
DIFFERENCES IN HEALTH CARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY
PHARMACOECONOMIC EVALUATION OF THE TREATMENT WITH OLANZAPINE IN “REVOLVING DOOR” SCHIZOPHRENIC PATIENTS
BARRIERS TO THE USE OF MEDICATIONS TO TREAT ALCOHOLISM
OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
SWITCHING AND AUGMENTATION OF ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS
PATTERNS OF ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATION USE IN MEDICAID, 1995–1999
DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS
AN INTERNET STUDY OF WTP FOR MIGRAINE PHARMACOTHERAPIES
USE OF GALANTAMINE IN THE NETHERLANDS FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE
THE IMPACT OF DEMENTIA ON CAREGIVER QUALITY OF LIFE
UTILITY ASSESSMENTS OF OPIOID TREATMENT IN THE US, CANADA AND AUSTRALIA FOR PATIENTS WITH CHRONIC NON-MALIGNANT PAIN
COMPARISON OF COSTS AND COST-EFFECTIVENESS OF OXCARBAZEPINE AND SODIUM VALPROATE FOR NEW/RECENT ONSET PARTIAL SEIZURES
VALIDATION OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) IN A SAMPLE OF HEADACHE SUFFERERS
A MODEL FOR PREDICTING THE INCIDENCE OF MIGRAINE IN THE IDAHO MEDICAID POPULATION
PSYCHOMETRIC EVALUATION OF WIDELY USED PAIN MEASURES FOR PURPOSE OF COMPUTERIZED DYNAMIC PAIN ASSESSMENT
HOW IS PAIN FELT ACROSS COUNTRIES? THE SHORT-FORM MCGILL PAIN QUESTIONNAIRE (SF-MPQ) IN 10 LANGUAGES
SURVIVAL AND NURSING HOME FREE SURVIVAL (NHFS) OF AD PATIENTS
THE MIGRAINE IN FRANCE IN 2000
DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE
DELAYS IN NURSING HOME PLACEMENT FOR PATIENTS WITH ALZHEIMER'S DISEASE ASSOCIATED WITH TREATMENT WITH DONEPEZIL MAY HAVE HEALTH CARE COST-SAVING IMPLICATIONS
A PROGNOSTIC MODEL TO PREDICT QUALITY OF LIFE CHANCES AFTER SUBARACHNOID HEMORRHAGE
MULTIPLE PAIN RELIEF ASSESSMENT IN WOMEN UNDERGOING NATURAL VERSUS EPIDURAL DELIVERY WITH ROPIVACAIN OR BUPIVACAIN
ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE DUE TO LOW BACK PAIN
ADDRESSING PARADOXES IN ECONOMIC EVALUATIONS (EES). AN EXAMPLE USING MOTOR NEURON DISEASE (MND)
COST SAVINGS IN MIGRAINE ASSOCIATED WITH LESS CHEST PAIN ON NEW TRIPTAN THERAPY
COMPARISON OF HUI2 AND HUI3 SCORES FOR PATIENTS WITH ALZHEIMER'S DISEASE
ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
MIGRAINE IN FRANCE IN 2000
HEALTH STATUS OF ELDERLY DIALYSIS PATIENTS
EVIDENCE OF DISEASE PROGRESSION IN ADULT PATIENTS WITH AN OVERACTIVE BLADDER (OAB)
PERSISTENCE OF THERAPY WITH DRUGS FOR OVERACTIVE BLADDER
ANALYSIS OF COMORBIDITY IN OVERACTIVE BLADDER AND URINARY INCONTINENCE IN A MANAGED CARE ORGANIZATION
THE IMPACT OF PHARMACOTHERAPY ON OVERACTIVE BLADDER SYMPTOM IMPROVEMENT AND RESOURCE UTILIZATION
THE RELIABILITY AND VALIDITY OF A NEW OAB-SPECIFIC HRQL QUESTIONNAIRE (OAB-Q)
CLINICAL CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE SCORES AND SUBSCALES AMONG CONSULTING AND NON-CONSULTING INDIVIDUALS WITH STRESS URINARY INCONTINENCE
THE INFLUENCE OF RACE ON SF-36 SCORES OF DIALYSIS PATIENTS
PREMATURE BIRTH AND RESOURCE UTILIZATION IN A LARGE EMPLOYMENT BASED INDEPENDENT PRACTICE ASSOCIATION (IPA)
A COST-MINIMIZATION ANALYSIS COMPARING MIRENA® WITH ORAL CONTRACEPTIVES
ERECTILE DYSFUNCTION
PHARMACIST-INITIATED EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA
HEALTH CARE USE ATTRIBUTABLE TO PROSTATE NON-SELECTIVE ALPHA-1 ANTAGONIST INITIATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH)
COST-EFFECTIVENESS OF INTRAVAGINAL PROSTAGLANDIN E2 GEL AND INTRAVAGINAL MISOPROSTOL FOR PREINDUCTION CERVICAL RIPENING
THE EFFECT AND ECONOMIC IMPACT OF STANDARDIZED ORDERS ON THE PREVENTION AND TREATMENT OF PONV IN HOSPITALIZED GYNECOLOGICAL SURGERY PATIENTS
QUALITY OF LIFE IN POST-MENOPAUSAL WOMEN IN FIVE EUROPEAN COUNTRIES
THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS
ATTITUDE OF PHYSICIANS TOWARD FORMULARIES AND SERVICES PROVIDED BY PHARMACIST
PHARMACOECONOMIC FELLOWSHIPS
DEVELOPING A COMPREHENSIVE PERFORMANCE MEASUREMENT DATA SET FOR PHARMACEUTICAL BENEFIT MANAGEMENT PROGRAMS
POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS IN COMPARISON TO INTERNATIONAL HEALTH ECONOMIC GUIDELINES
ACTIVITIES, FUNCTIONS AND STRUCTURE OF PHARMACY AND THERAPEUTICS COMMITTEES IN ISRAELI HOSPITALS
APPLICATION OF HEALTH ECONOMICS IN THE CANADIAN PHARMACEUTICAL INDUSTRY
PRACTICE USE OF PHARMACOECONOMICS DATA IN HOSPITAL FORMULARY DECISIONS
COMPARISON OF TECHNOLOGY ASSESSMENT IN LARGE MEDICAL GROUPS AND HEALTH MAINTENANCE ORGANIZATIONS (HMOS)
THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE
USE OF THE ANDERSEN HEALTH CARE SERVICES UTILIZATION BEHAVIORAL MODEL TO UNDERSTAND THE RELATIONSHIP BETWEEN HEALTH INSURANCE COVERAGE AND HEALTH CARE SERVICES UTILIZATION AMONG THE ELDERLY
ACUTE CARE ELDERLY UNITS
INDICES FOR EVALUATION OF DRUG COST/UTILIZATION
COST ANALYSIS OF PHARMACEUTICAL SERVICES IN A TEACHING INSTITUTION
A SURVEY OF PUBLIC HOSPITAL PHARMACISTS IN SINGAPORE ON THEIR VIEWS ABOUT ‘THE FORMULARY’ AND ITS DECISION-MAKING PROCESS
THE VALUE OF VARIOUS FORMS OF EVIDENCE IN DRUG FORMULARY DECISION MAKING
PATIENT OUTCOMES IN THE SEDATED ICU PATIENT
A MODEL FOR COMPARING COSTS ASSOCIATED WITH PRESCRIPTION WASTAGE WITH APPLICATION TO VA PRESCRIPTION DATA
USING FINANCIAL RATIOS TO COMPARE PHARMACY SPENDING IN THE DEPARTMENT OF VETERANS AFFAIRS
THE LAG BETWEEN EFFECTIVENESS AND COST-EFFECTIVENESS EVIDENCE OF NEW DRUGS AND DECISION-MAKING IN HEALTH CARE
SINGLE EUROPEAN-LEVEL COST-EFFECTIVENESS ANALYSIS
PATIENT ADHERENCE TO DRUG THERAPY IN A THREE-TIER COPAYMENT STRUCTURE
DRUG REIMBURSEMENT PROGRAM FOR INDIGENT PATIENTS
LESSONS LEARNED FROM DEVELOPING A PSYCHOMETRICALLY BASED SEDATION QUESTIONNAIRE IN PHARMACOLOGICALLY PARALYZED CRITICALLY ILL PATIENTS
ROLE OF HEALTH RELATED QUALITY OF LIFE OUTCOMES IN THE EUROPEAN DRUG REGULATORY PROCESS
DEFINING CLINICALLY MEANINGFUL CHANGE IN HEALTH-RELATED QUALITY OF LIFE
CROSS-CULTURAL VARIATIONS IN SF-12 SCORES AMONG INDIVIDUALS WITH VARIOUS HEALTH CONDITIONS
TRANSLATING SF-36 SCORES INTO PREFERENCES
HEALTH UTILITIES INDEX MARK 3
IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE?
EVALUATING BIAS INTRODUCED BY ANNUALIZING UTILIZATION AND COST MEASURES
QUALITY OF LIFE OF PATIENTS WITH FABRY DISEASE
NEGATIVE AFFECTIVITY
THE HEALTH AND WORK QUESTIONNAIRE (HWQ)
METHODOLOGICAL ADVANCES IN THE ASSESSMENT OF QUALITY OF LIFE IN CLINICAL TRIALS
DEVELOPMENT OF COST-EFFECTIVE WEB-BASED OUTCOMES RESEARCH STUDIES AND DISEASE MANAGEMENT PROGRAMS
DOES WHERE YOU LIVE AFFECT IF AND HOW YOU DISCOUNT FUTURE COSTS AND BENEFITS IN ECONOMIC EVALUATION? SHOULD IT?
AN ECONOMIC PROOF AND APPLICATION THAT FORMULARY RESTRICTIONS WITHIN DRUG CLASSES ALWAYS RESULT IN HIGHER COSTS
A RISK ADJUSTMENT METHODOLOGY FOR CLAIMS DATA
THE REDUCTION OF SAMPLE SIZE FOR A COST-EFFECTIVENESS TRIAL USING A NEW METHOD
CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING
DEVELOPMENT OF A CHRONIC DISEASE INDICATOR USING A MANAGED CARE POPULATION
BAYESIAN OR CLASSICAL DESIGN AND ANALYSIS
DESCRIPTION OF COST/EFFECTIVENESS RATIO DISTRIBUTIONS
COMPARISON OF STATISTICAL TESTS FOR THE COST/EFFECTIVENESS RATIOS
RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION
RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION
BAYESIAN DECISION ANALYSIS IN OUTCOME STUDIES WITH SMALL NUMBERS OF EVENTS
CONDUCTING PHARMACOECONOMIC RESEARCH IN THE ABSENCE OF COUNTRY-SPECIFIC DATA
CONFIRMATION OF THE DECISION RULES AND ASSUMPTIONS FOR A MODEL OF DIABETES TREATMENT USING AN EXPERT PANEL
THE EUROPEAN SERVICE MAPPING SCHEDULE (ESMS)
THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®)
METHODOLOGICAL COMPLEXITIES IN USING ADMINISTRATIVE CLAIMS DATABASES TO EVALUATE QUALITY OF CARE FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
USING LINKABLE CLINICAL AND ADMINISTRATIVE CLAIMS DATA TO IMPROVE OUTCOMES RESEARCH
Issues And Problems Encountered In Models On Prevention Of Deep Venous Thrombosis (DVT)
A New Approach To Disease Modeling With Numerous Comparators And Multiple Decision Trees
CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA
CONDUCTING COST-BENEFIT AND COST-UTILITY ANALYSES
BEYOND COST-EFFECTIVENESS
CONSTRUCTING EPISODES OF CARE FROM CLAIMS DATA
THE USE OF MULTI-ATTRIBUTE ANALYSIS AND PAIR-WISE COMPARISONS FOR GROUP DECISION-MAKING
MULTINATIONAL ECONOMIC STUDIES
USING MARKOV DECISION MODELS TO DEVELOP OPTIMAL TREATMENT PATHWAYS
USE OF MEDICATION COMPLIANCE DATA IN OUTCOME ANALYSES
CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH
MAKING MODELS BETTER
IDENTIFYING THE IMPACT OF A TREATMENT ON OUTCOMES AND COSTS USING OBSERVATIONAL DATA
PATIENT REGISTRIES
SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES
THE ROLE OF HEALTH STATE EXPERIENCE IN LONGITUDINAL CONJOINT ANALYSIS OF PATIENT PREFERENCES